Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines…
News
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer…
Modifi Bio Announces Scientific Advisory Board
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trials NEW…
Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All…
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer…
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine…
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
In December 2022, the 15th patient was dosed with IMX-110 IMX-110 clinical trial data expected…
Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model…
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the…
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy…
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and…
BioSyent Announces Renewal of Normal Course Issuer Bid
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
Thursday, December 15, 2022 @ 8:00 AM ET DURHAM, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE)…
Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting
Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence…
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis
Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD,…
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from…
Syneos Health Extends Partnership with Medable
Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient MORRISVILLE, N.C., Dec. 13,…